
Curis, Inc. (NASDAQ:CRIS – Free Report) – Analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of Curis in a research report issued on Friday, November 13th. HC Wainwright analyst S. Nik now expects that the biotechnology company will post earnings of ($8.05) per share for the year, up from their prior forecast of ($15.65). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Curis’ current full-year earnings is ($8.05) per share. HC Wainwright also issued estimates for Curis’ Q4 2026 earnings at ($0.51) EPS and FY2027 earnings at ($0.65) EPS.
Several other equities research analysts also recently commented on CRIS. Wall Street Zen upgraded Curis from a “strong sell” rating to a “hold” rating in a report on Saturday, August 22nd. Zacks Research upgraded Curis from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $43.00.
Curis Stock Up 13.4%
Shares of CRIS stock opened at $0.61 on Tuesday. Curis has a 52 week low of $0.33 and a 52 week high of $28.40. The firm has a 50 day moving average of $0.72 and a 200-day moving average of $7.94.
Curis (NASDAQ:CRIS – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The biotechnology company reported ($1.94) EPS for the quarter, topping analysts’ consensus estimates of ($2.01) by $0.07.
Institutional Investors Weigh In On Curis
Institutional investors and hedge funds have recently bought and sold shares of the stock. Focused Wealth Management Inc bought a new position in Curis during the 2nd quarter valued at $26,000. BlackRock Inc. bought a new stake in shares of Curis in the 2nd quarter worth $28,000. Flputnam Investment Management Co. bought a new stake in shares of Curis in the 2nd quarter worth $128,000. Renaissance Technologies LLC grew its stake in shares of Curis by 52.2% in the 1st quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 125,823 shares in the last quarter. Finally, Cable Car Capital LP bought a new stake in shares of Curis in the 2nd quarter worth $696,000. 29.97% of the stock is owned by hedge funds and other institutional investors.
About Curis
Curis, Inc. is a clinical-stage biotechnology company focused on developing treatments for cancer. Its research centers on targeted therapies designed to interfere with biological pathways involved in tumor growth and survival. The company’s clinical pipeline has included emavusertib, an oral small-molecule inhibitor of IRAK4 and FLT3 being investigated for certain blood cancers and other malignancies. Curis has also worked with partners to develop cancer drug candidates. Historically, Curis collaborated with Genentech on the development of Erivedge (vismodegib), a Hedgehog pathway inhibitor approved to treat certain cases of advanced basal cell carcinoma.
Featured Articles
- Five stocks we like better than Curis
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
